Emerging innovations in clinical trial design

Designs of clinical trials have changed little since the advent of randomization in the 1940s. Modern innovations in designs are being driven by the increasing recognition in clinical research that diseases are heterogeneous and patients who apparently have the same disease require different therapies. This article describes some innovations in clinical trial design across therapeutic areas but with a focus on oncology. No one knows what the future holds for clinical trial design but the status quo of large trials that pretend the patient population is homogeneous is not sustainable, either economically or scientifically/medically. No one knows what the eventual business model and regulatory model will be, but they will be very different from today's.

[1]  Sabine Schulze,et al.  Statistics A Bayesian Perspective , 2016 .

[2]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[3]  Brenda Gaydos,et al.  Application of Adaptive Design Methodology in Development of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Statistical Design and Simulations , 2012, Journal of diabetes science and technology.

[4]  Nathalie Seigneuret,et al.  The Innovative Medicines Initiative: an engine for regulatory science , 2014, Nature Reviews Drug Discovery.

[5]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[6]  J. Witmer.  Bayesian Multistage Decision Problems , 1986 .

[7]  T L Lai,et al.  Sequential medical trials. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Berry,et al.  Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. , 2012, American heart journal.

[9]  J. Neyman,et al.  INADMISSIBILITY OF THE USUAL ESTIMATOR FOR THE MEAN OF A MULTIVARIATE NORMAL DISTRIBUTION , 2005 .

[10]  Draft Guidance.  Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics DRAFT GUIDANCE , 2010 .

[11]  Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer : Use as an Endpoint to Support Accelerated Approval , 2014 .

[12]  Donald A. Berry,et al.  Modified Two-Armed Bandit Strategies for Certain Clinical Trials , 1978 .

[13]  D A Berry,et al.  A case for Bayesianism in clinical trials. , 1993, Statistics in medicine.

[14]  D. Berry.  Bayesian Statistics and the Efficiency and Ethics of Clinical Trials , 2004 .

[15]  D. Berry.  Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.

[16]  D. Berry.  Adaptive clinical trials in oncology , 2012, Nature Reviews Clinical Oncology.

[17]  D. Berry,et al.  Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL , 2013 .

[18]  D. Berry,et al.  Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. , 1995, Statistics in medicine.

[19]  Donald A Berry,et al.  The Brave New World of clinical cancer research: Adaptive biomarker‐driven trials integrating clinical practice with clinical research , 2015, Molecular oncology.

[20]  D. Berry,et al.  Choosing sample size for a clinical trial using decision analysis , 2003 .

[21]  D. Berry,et al.  I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.

[22]  G. Wassmer,et al.  Comments on the Draft Guidance on “Adaptive Design Clinical Trials for Drugs and Biologics” of the U.S. Food and Drug Administration , 2010, Journal of biopharmaceutical statistics.

[23]  Bradley P. Carlin,et al.  Bayesian Adaptive Methods for Clinical Trials , 2010 .

[24]  Michael D. Smith,et al.  Adaptive Bayesian Designs for Dose-Ranging Drug Trials , 2002 .

[25]  T. Colton.  A Model for Selecting One of Two Medical Treatments , 1963 .

[26]  C. Stein,et al.  Estimation with Quadratic Loss , 1992 .

[27]  Diane D. Liu,et al.  Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center , 2009, Clinical trials.

[28]  B. Efron,et al.  Stein's Paradox in Statistics , 1977 .

[29]  M. Fuerst.  Medullary Thyroid Cancer: Cabozantinib Extends PFS in Patients with RET or RAS Mutations , 2013 .

[30]  S. Stein,et al.  The Signature Program: Bringing the Protocol to the Patient , 2015, Clinical pharmacology and therapeutics.

[31]  J. Chien,et al.  An Adaptive, Dose-Finding, Seamless Phase 2/3 Study of a Long-Acting Glucagon-like Peptide-1 Analog (Dulaglutide): Trial Design and Baseline Characteristics , 2012, Journal of diabetes science and technology.